Prelude Therapeutics Inc (PRLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 218,309 | 234,792 | 0 | 0 | N/A |
| TOTAL | $220,809 | $238,061 | $0 | $0 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 2,480 | 1,620 | N/A | N/A | N/A |
| Other Non-Current Assets | 301 | 0 | 0 | 0 | 0 |
| TOTAL | $2,781 | $1,620 | $N/A | $N/A | $N/A |
| Total Assets | $223,590 | $239,681 | $0 | $0 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,920 | 5,074 | 0 | 0 | 0 |
| Accrued Expenses | 7,455 | 6,285 | 0 | 0 | N/A |
| TOTAL | $11,375 | $11,359 | $0 | $0 | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 32 | 15 | 0 | 0 | 0 |
| TOTAL | $32 | $15 | $N/A | $N/A | $N/A |
| Total Liabilities | $11,407 | $11,374 | $0 | $0 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 46,586 | 43,703 | N/A | N/A | N/A |
| Common Shares | 4 | 4 | 0 | 0 | N/A |
| Retained earnings | -107,426 | -88,176 | 0 | 0 | N/A |
| TOTAL | $212,183 | $228,307 | $0 | $0 | $N/A |
| Total Liabilities And Equity | $223,590 | $239,681 | $0 | $0 | $0 |